Cannabinoid CB1 receptors control conditioned drug seeking

Taco J De Vries, Anton N M Schoffelmeer

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Recent developments have implicated cannabinoid CB1 receptors as a novel target for a new class of therapeutic agents used to treat drug addiction. CB1 receptors are expressed in the motivational circuitry of the brain and modulate drug seeking. Blockade of the CB1 receptor is particularly effective in reducing cue-induced reinstatement of drug seeking, an animal analogue of cue-induced relapse in human addicts. These relapse-preventing properties are observed with different classes of abused drug (i.e. psychostimulants, opiates, nicotine and alcohol). In addition, recent evidence indicates a more general role of CB1 receptors in reward-related memories, which is consistent with the proposed role of endocannabinoids in memory-related plasticity. Relapse-preventing actions and inhibitory effects on weight gain were confirmed recently in clinical trials with the CB1 antagonist rimonabant. Collectively, these clinical and preclinical studies suggest that antagonists of CB1 receptors offer a novel approach in the treatment of addictive behaviours.

Original languageEnglish
Pages (from-to)420-6
Number of pages7
JournalTrends in Pharmacological Sciences
Volume26
Issue number8
DOIs
Publication statusPublished - Aug 2005

Cite this

@article{872cc35e946841d6a6b22dee7d2a43e6,
title = "Cannabinoid CB1 receptors control conditioned drug seeking",
abstract = "Recent developments have implicated cannabinoid CB1 receptors as a novel target for a new class of therapeutic agents used to treat drug addiction. CB1 receptors are expressed in the motivational circuitry of the brain and modulate drug seeking. Blockade of the CB1 receptor is particularly effective in reducing cue-induced reinstatement of drug seeking, an animal analogue of cue-induced relapse in human addicts. These relapse-preventing properties are observed with different classes of abused drug (i.e. psychostimulants, opiates, nicotine and alcohol). In addition, recent evidence indicates a more general role of CB1 receptors in reward-related memories, which is consistent with the proposed role of endocannabinoids in memory-related plasticity. Relapse-preventing actions and inhibitory effects on weight gain were confirmed recently in clinical trials with the CB1 antagonist rimonabant. Collectively, these clinical and preclinical studies suggest that antagonists of CB1 receptors offer a novel approach in the treatment of addictive behaviours.",
keywords = "Animals, Conditioning (Psychology), Disease Models, Animal, Humans, Piperidines, Pyrazoles, Receptor, Cannabinoid, CB1, Signal Transduction, Substance-Related Disorders, Journal Article, Review",
author = "{De Vries}, {Taco J} and Schoffelmeer, {Anton N M}",
year = "2005",
month = "8",
doi = "10.1016/j.tips.2005.06.002",
language = "English",
volume = "26",
pages = "420--6",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "8",

}

Cannabinoid CB1 receptors control conditioned drug seeking. / De Vries, Taco J; Schoffelmeer, Anton N M.

In: Trends in Pharmacological Sciences, Vol. 26, No. 8, 08.2005, p. 420-6.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Cannabinoid CB1 receptors control conditioned drug seeking

AU - De Vries, Taco J

AU - Schoffelmeer, Anton N M

PY - 2005/8

Y1 - 2005/8

N2 - Recent developments have implicated cannabinoid CB1 receptors as a novel target for a new class of therapeutic agents used to treat drug addiction. CB1 receptors are expressed in the motivational circuitry of the brain and modulate drug seeking. Blockade of the CB1 receptor is particularly effective in reducing cue-induced reinstatement of drug seeking, an animal analogue of cue-induced relapse in human addicts. These relapse-preventing properties are observed with different classes of abused drug (i.e. psychostimulants, opiates, nicotine and alcohol). In addition, recent evidence indicates a more general role of CB1 receptors in reward-related memories, which is consistent with the proposed role of endocannabinoids in memory-related plasticity. Relapse-preventing actions and inhibitory effects on weight gain were confirmed recently in clinical trials with the CB1 antagonist rimonabant. Collectively, these clinical and preclinical studies suggest that antagonists of CB1 receptors offer a novel approach in the treatment of addictive behaviours.

AB - Recent developments have implicated cannabinoid CB1 receptors as a novel target for a new class of therapeutic agents used to treat drug addiction. CB1 receptors are expressed in the motivational circuitry of the brain and modulate drug seeking. Blockade of the CB1 receptor is particularly effective in reducing cue-induced reinstatement of drug seeking, an animal analogue of cue-induced relapse in human addicts. These relapse-preventing properties are observed with different classes of abused drug (i.e. psychostimulants, opiates, nicotine and alcohol). In addition, recent evidence indicates a more general role of CB1 receptors in reward-related memories, which is consistent with the proposed role of endocannabinoids in memory-related plasticity. Relapse-preventing actions and inhibitory effects on weight gain were confirmed recently in clinical trials with the CB1 antagonist rimonabant. Collectively, these clinical and preclinical studies suggest that antagonists of CB1 receptors offer a novel approach in the treatment of addictive behaviours.

KW - Animals

KW - Conditioning (Psychology)

KW - Disease Models, Animal

KW - Humans

KW - Piperidines

KW - Pyrazoles

KW - Receptor, Cannabinoid, CB1

KW - Signal Transduction

KW - Substance-Related Disorders

KW - Journal Article

KW - Review

U2 - 10.1016/j.tips.2005.06.002

DO - 10.1016/j.tips.2005.06.002

M3 - Article

VL - 26

SP - 420

EP - 426

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 8

ER -